For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …

Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free
factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …

Cardiovascular diseases are still the most important cause of morbidity and mortality
worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs …

Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers
Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for …

An ability to readily determine an anticoagulant effect with an emerging class of direct, active
site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some …